TY - JOUR
T1 - How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers?
AU - Betancor, Diana
AU - Olaguibel, José María
AU - Rodrigo-Muñoz, José Manuel
AU - Arismendi, Ebymar
AU - Barranco, Pilar
AU - Barroso, Blanca
AU - Bobolea, Irina
AU - Cárdaba, Blanca
AU - Cruz, María Jesús
AU - Curto, Elena
AU - Del Pozo, Victoria
AU - González-Barcala, Francisco Javier
AU - Martínez-Rivera, Carlos
AU - Mullol, Joaquim
AU - Muñoz, Xavier
AU - Picado, Cesar
AU - Plaza, Vicente
AU - Quirce, Santiago
AU - Rial, Manuel Jorge
AU - Soto, Lorena
AU - Valero, Antonio
AU - Valverde-Monge, Marcela
AU - Sastre, Joaquin
N1 - Publisher Copyright:
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
PY - 2022/8/20
Y1 - 2022/8/20
N2 - Background and Aims: Asthma is a heterogeneous respiratory disease that encompasses different inflammatory and functional endophenotypes. Many non-invasive biomarkers has been investigated to its pathobiology. Heany et al proposed a clinical algorithm that classifies severe asthmatic patients into likely-eosinophilic phenotypes, based on accessible biomarkers: PBE, current treatment, FeNO, presence of nasal polyps (NP) and age of onset. Materials and Methods: We assessed the concordance between the algorithm proposed by Heany et al. with sputum examination, the gold standard, in 145 asthmatic patients of the MEGA cohort with varying grades of severity. Results: No correlation was found between both classifications 0.025 (CI = 0.013–0.037). Moreover, no relationship was found between sputum eosinophilia and peripheral blood eosinophilia count in the total studied population. Discussion and Conclusion: In conclusion, our results suggest that grouping the biomarkers proposed by Heany et al. are insufficient to diagnose eosinophilic phenotypes in asthmatic patients. Sputum analysis remains the gold standard to assess airway inflammation.
AB - Background and Aims: Asthma is a heterogeneous respiratory disease that encompasses different inflammatory and functional endophenotypes. Many non-invasive biomarkers has been investigated to its pathobiology. Heany et al proposed a clinical algorithm that classifies severe asthmatic patients into likely-eosinophilic phenotypes, based on accessible biomarkers: PBE, current treatment, FeNO, presence of nasal polyps (NP) and age of onset. Materials and Methods: We assessed the concordance between the algorithm proposed by Heany et al. with sputum examination, the gold standard, in 145 asthmatic patients of the MEGA cohort with varying grades of severity. Results: No correlation was found between both classifications 0.025 (CI = 0.013–0.037). Moreover, no relationship was found between sputum eosinophilia and peripheral blood eosinophilia count in the total studied population. Discussion and Conclusion: In conclusion, our results suggest that grouping the biomarkers proposed by Heany et al. are insufficient to diagnose eosinophilic phenotypes in asthmatic patients. Sputum analysis remains the gold standard to assess airway inflammation.
KW - asthma
KW - biomarkers
KW - eosinophils
KW - exhaled nitric oxide
KW - non-eosinophilic
KW - phenotypes
KW - sputum
UR - http://www.scopus.com/inward/record.url?scp=85136897413&partnerID=8YFLogxK
U2 - 10.1002/clt2.12182
DO - 10.1002/clt2.12182
M3 - Article
C2 - 36000018
AN - SCOPUS:85136897413
SN - 2045-7022
VL - 12
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 8
M1 - e12182
ER -